ProfileGDS5678 / 1419103_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 60% 64% 66% 65% 65% 32% 56% 69% 67% 50% 69% 55% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8080663
GSM967853U87-EV human glioblastoma xenograft - Control 23.5840560
GSM967854U87-EV human glioblastoma xenograft - Control 33.836964
GSM967855U87-EV human glioblastoma xenograft - Control 43.9570766
GSM967856U87-EV human glioblastoma xenograft - Control 53.8687765
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9525965
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7888432
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4080656
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2707469
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1133967
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1825750
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2543769
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3828655
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7653363